The company noted a steep decline in elective procedure volumes at the end of the first quarter and is projecting a “significant negative impact” in the second quarter.
Seven things to know:
1. First-quarter net sales decreased 9.7 percent to $1.78 billion year over year.
2. The company’s dental, spine and craniomaxillofacial and thoracic sales decreased 12.4 percent to $252 million, compared to the same period in 2019.
3. Knee sales in the first quarter decreased 9.3 percent to $630 million and hip sales fell 10.3 percent to $433 million year over year.
4. The company’s sports medicine, extremities and trauma sales dropped 6.5 percent in the first quarter to $333 million.
5. Diluted loss per share was $2.46 for the first quarter. Adjusted diluted earnings per share were $1.70, representing a 9.1 decrease year over year.
6. While Zimmer Biomet’s first quarter financial results were severely impacted by COVID-19, its operational performance was “trending ahead of our expectations” prior to the pandemic, according to CEO Bryan Hanson.
7. Due to the uncertainty surrounding the duration of the COVID-19 pandemic, the company is not providing a full-year financial forecast.
More articles on devices:
AAOS, OREF partner to drive funding for biologic, total joint replacement research
NuVasive Q1 net income drops 43.6%, shares down 27% since start of year
Dr. Charles Branch Jr.: Imaging, patient engagement big opportunities in spine post-pandemic
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
